2022 World Conference on Lung Cancer (ePosters)-EP08.02-014. Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort

Pdf Summary

A new study conducted in Canada examined the impact of East Asian ancestry on the response to the first-line lung cancer treatment, osimertinib. The study included a cohort of 77 patients with EGFR-mutant non-small cell lung cancer who were treated with osimertinib.<br /><br />EGFR mutations are common in lung adenocarcinoma, but their prevalence varies among different populations. Patients of East Asian ancestry have a higher incidence of EGFR mutations compared to Caucasian populations. Osimertinib is a third-generation EGFR inhibitor that has shown effectiveness in treating EGFR-mutant lung cancer. However, previous research has suggested that patients of Asian ancestry may have a better response to earlier generation EGFR inhibitors.<br /><br />In this study, the researchers compared the demographic and clinical characteristics as well as the response to osimertinib between Asian and non-Asian patients. The cohort was predominantly female, never-smokers, and over the age of 65 at diagnosis. There were no significant differences in demographics or clinical characteristics between the Asian and non-Asian cohorts.<br /><br />The study found that patients of Asian ancestry had a significantly shorter time to progression on osimertinib compared to non-Asian patients. However, despite the shorter time to progression, Asian patients still had a significantly better clinical response to osimertinib.<br /><br />The researchers suggest that further investigations are needed to understand the potential differential response to osimertinib based on racial ancestry. They also found that early termination of osimertinib treatment due to adverse events was more common in non-Asian patients.<br /><br />Overall, this study highlights the potential impact of East Asian ancestry on the response to osimertinib treatment in EGFR-mutant non-small cell lung cancer. It emphasizes the need for personalized treatment approaches based on individual patient characteristics, including racial ancestry.

Asset Subtitle

Amanda Gibson

Meta Tag

Speaker Amanda Gibson

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Canada

East Asian ancestry

lung cancer treatment

osimertinib

EGFR-mutant non-small cell lung cancer

EGFR mutations

Caucasian populations

third-generation EGFR inhibitor

Asian patients

racial ancestry